| [Bladder preservation possibilities in the treatment of muscle-invasive bladder cancer]. | |
| | |
MedLine Citation:
|
PMID: 17090976 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Radical cystectomy is the standard of treatment for muscle-invasive transitional cell carcinoma of the bladder in European Union and in United States. During the last few decades, several clinical trials were performed with the aim to evaluate new treatment methods as an alternative to radical cystectomy for selected patient groups. According to some clinical trials, it is clear that bladder preservation is possible without compromising overall survival of these patients. Organ preservation requires a combined-modality treatment including transurethral resection of bladder tumor, radiation therapy, and systemic chemotherapy. Incorporation of chemotherapeutic agents such as gemcitabine or taxanes in bladder-sparing protocols improves the results of conservative treatment of locally advanced bladder cancer. Pretreatment selection criteria and the most important prognostic factors are macroscopically complete transurethral resection of bladder tumor, absence of hydronephrosis, and lower T stage. |
| | |
Authors:
|
Jolita Asadauskiene; Eduardas Aleknavicius; Terese Pipiriene Zelviene; Feliksas Jankevicius |
Publication Detail:
|
Type: English Abstract; Journal Article; Review |
Journal Detail:
|
Title: Medicina (Kaunas, Lithuania) Volume: 42 ISSN: 1648-9144 ISO Abbreviation: Medicina (Kaunas) Publication Date: 2006 |
Date Detail:
|
Created Date: 2006-11-08 Completed Date: 2006-12-18 Revised Date: 2013-06-03 |
Medline Journal Info:
|
Nlm Unique ID: 9425208 Medline TA: Medicina (Kaunas) Country: Lithuania |
Other Details:
|
Languages: lit Pagination: 781-7 Citation Subset: IM |
Affiliation:
|
Institute of Oncology, Vilnius University, Vilnius, Lithuania. |
Vernacular Title:
|
Serganciuju invaziniu uroteliniu veziu slapimo pūsle issaugancio gydymo efektyvumas. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antimetabolites, Antineoplastic
/
administration & dosage,
therapeutic use Antineoplastic Agents / administration & dosage, therapeutic use Antineoplastic Combined Chemotherapy Protocols / therapeutic use Carboplatin / administration & dosage, therapeutic use Carcinoma, Transitional Cell / drug therapy, mortality, pathology, radiotherapy, therapy Cisplatin / administration & dosage, therapeutic use Clinical Trials as Topic Clinical Trials, Phase I as Topic Clinical Trials, Phase II as Topic Combined Modality Therapy Cystectomy Deoxycytidine / administration & dosage, analogs & derivatives, therapeutic use Disease-Free Survival Dose Fractionation Doxorubicin / therapeutic use Humans Methotrexate / therapeutic use Neoplasm Invasiveness Neoplasm Staging Prognosis Radiation-Sensitizing Agents / administration & dosage, therapeutic use Radiotherapy Dosage Taxoids / administration & dosage, therapeutic use Time Factors Urinary Bladder / pathology Urinary Bladder Neoplasms / drug therapy, mortality, pathology, radiotherapy, surgery, therapy* Vinblastine / therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Antimetabolites, Antineoplastic; 0/Antineoplastic Agents; 0/Radiation-Sensitizing Agents; 0/Taxoids; 15663-27-1/Cisplatin; 23214-92-8/Doxorubicin; 41575-94-4/Carboplatin; 59-05-2/Methotrexate; 865-21-4/Vinblastine; 951-77-9/Deoxycytidine; B76N6SBZ8R/gemcitabine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Cognitive function, habitual gait speed, and late-life disability in the National Health and Nutriti...
Next Document: Exercise as a stressor to the human neuroendocrine system.